Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$11.77
+5.9%
$10.77
$7.56
$66.64
$6.36M1.3563,213 shs104,463 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
$0.04
-8.5%
$0.05
$0.03
$0.10
$8.28M-0.594,340 shs9,800 shs
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
$0.00
-53.3%
$0.00
$0.00
$0.00
$1.42M0.14376,106 shs24,224 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
+5.94%+5.56%+22.45%-17.09%-80.08%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
-8.54%+5.02%-18.70%-12.20%-48.35%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
-53.33%-53.33%-65.00%-12.50%-66.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
2.5396 of 5 stars
3.54.00.00.00.61.70.6
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.00
Buy$238.001,922.09% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
0.00
N/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$10.84 per shareN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/A$0.01 per shareN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$15.02M-$41.74N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
-$3.34M-$0.01N/AN/AN/A-120.86%-55.21%8/4/2025 (Estimated)
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
-$2.10MN/A0.00N/AN/AN/AN/AN/A

Latest RSPI, INNVD, INTI, and INDP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$11.48-$8.96+$2.52-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
1.90
1.90
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/A
46.68
46.68
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
6570,000453,000Not Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
1172.57 million164.64 millionNot Optionable
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
2949.46 million474.45 millionNot Optionable

Recent News About These Companies

RespireRx Pharmaceuticals Inc (RSPI)
RespireRx Pharmaceuticals Inc RSPI
RCKT Rocket Pharmaceuticals, Inc.
Other OTC Pharmaceuticals - Haiti
Other OTC Pharmaceuticals - Vietnam
Other OTC Pharmaceuticals - Finland
Alnylam Pharmaceuticals (NASDAQ: ALNY)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$11.77 +0.66 (+5.94%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$11.59 -0.18 (-1.54%)
As of 07/8/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Inhibitor Therapeutics stock logo

Inhibitor Therapeutics OTCMKTS:INTI

$0.04 0.00 (-8.54%)
As of 07/8/2025 03:02 PM Eastern

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Cortex Pharmaceuticals stock logo

Cortex Pharmaceuticals OTCMKTS:RSPI

$0.0007 0.00 (-53.33%)
As of 07/8/2025 03:53 PM Eastern

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.